The final patient has completed the treatment stage of a phase 2b clinical trial investigating NCX 4251 for blepharitis, according to a press release from Nicox.
The Mississippi trial, which is investigating NCX 4251 0.1% (fluticasone propionate nanocrystals ophthalmic suspension), recruited more than 200 patients. The primary outcome measures include the proportion of patients on NCX 4251 vs. placebo who achieve a complete cure in eyelid redness, eyelid debris and eyelid discomfort at day 15.
“The Mississippi trial includes a number of clinical endpoints related to signs and symptoms of